SARS-CoV-2 variants - Practical considerations for accelerated clinical development in light of current regulatory guidance
Meeting Norms and Recording Disclaimer

• Throughout the workshop, please ask any questions in the “Q&A” function. If you see that your question is already asked, you can “like” the question in the “Q&A” function.

• This workshop will be recorded. Please be mindful of the diverse audience attending the meeting when participating in open discussions.
# Workshop Agenda

<table>
<thead>
<tr>
<th>Time (CET)</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:20</td>
<td><strong>Part 1: Welcome and Meeting Objectives</strong></td>
<td>Peter Dull</td>
</tr>
<tr>
<td>14:20-14:35</td>
<td>General Overview of Regulatory Framework for Variant Vaccines</td>
<td>Jakob Cramer</td>
</tr>
<tr>
<td>14:35-14:45</td>
<td>Variants and Vaccines: Global Public Health Implications</td>
<td>Sylvie Briand</td>
</tr>
<tr>
<td>14:45-14:55</td>
<td>Regulatory Preparedness on Adapting, if Needed, Vaccines for Strain Changes</td>
<td>David Wood</td>
</tr>
<tr>
<td>14:55-15:10</td>
<td>US, EU, ACCESS and WHO Guidance on Strain Change</td>
<td>Adam Hacker</td>
</tr>
<tr>
<td>15:10-15:15</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>15:15-17:00</td>
<td><strong>Part 2: Use Cases &amp; Panel Discussions</strong></td>
<td></td>
</tr>
<tr>
<td>15:15-15:30</td>
<td>Approach for Vaccines with Acceptable Efficacy Data (with or without EUA / full registration)</td>
<td></td>
</tr>
<tr>
<td>15:30-15:50</td>
<td>Panel Discussion</td>
<td>Moderated by: Jakob Cramer</td>
</tr>
<tr>
<td>15:50-16:10</td>
<td>Approach for vaccines lacking efficacy data</td>
<td></td>
</tr>
<tr>
<td>16:10-16:50</td>
<td>Panel Discussion</td>
<td>Moderated by: Peter Dull</td>
</tr>
<tr>
<td>16:50-17:00</td>
<td>Wrap Up &amp; Next Steps</td>
<td>Jakob Cramer</td>
</tr>
</tbody>
</table>
Welcome & Meeting Objectives

Peter Dull, MD
Deputy Director,
Integrated Clinical Vaccine Development,
Bill & Melinda Gates Foundation (BMGF)
Why do we need more COVID-19 vaccines?

- Current models predict that there will not be enough vaccines to cover the world’s population until 2023 or 2024
  - High-income countries already own more than half of all global doses purchased.

- Manufacturing capacity for existing vaccines has expansion limits
  - Tech transfers are complicated and scale-up ambitions have not been realized with supply chain bottlenecks for existing products

- Evolving variants are a concern
  - Emerging variants are spreading rapidly, and early data shows resistance to current vaccines
  - Urgent need to accelerate vaccine development for the new variants

- The world needs more, and possibly different, vaccines
  - Recent trans-national limits of vaccine highlight the need for a diversified vaccine supply
Identification of a biomarker that is reasonably likely to predict protection against COVID-19 would enable accelerated evaluations of high potential new vaccines.

Once additional understanding of SARS-CoV-2 immunology, and specifically vaccine immune responses that might be reasonably likely to predict protection against COVID-19, is acquired, accelerated approval of a COVID-19 vaccine…may be considered if an applicant provides sufficient data and information to meet the applicable legal requirements.


NB: “…companies are still required to conduct studies to confirm the anticipated clinical benefit”

Critical question we must ask as data accumulates: As we move down the road to a quantitative threshold, have we already arrived at a sufficiently confident relationship between a biomarker and vaccine efficacy?
Two independent studies find strong correlation between antibody titers and efficacy, suggesting a potential correlate of protection.

**What level of neutralizing antibody protects from COVID-19?**

*Pre-print posted 11 March 2021*

David S Khoury, Deborah Cromer, Arnold Reynaldi, Timothy E Schlub, Adam K Wheatley, Jennifer A Juno, Kanta Subbarao, Stephen J Kent, James A Triccas, Miles P Davenport

doi: https://doi.org/10.1101/2021.03.09.21252641

**Evidence for antibody as a protective correlate for COVID-19 vaccines**

*Pre-print posted 20 March 2021*

Kristen A. Earle, Donna M. Ambrosino, Andrew Fiore-Gartland, David Goldblatt, Peter B. Gilbert, George R. Siber, Peter Dull, Stanley A. Plotkin

doi: https://doi.org/10.1101/2021.03.17.2000246

Robust correlation despite diverse study populations subject to different forces of infection and circulating variants, and use of different endpoints, assays, convalescent sera panels and manufacturing platforms.
Strong non-linear relationship \((\rho = 0.905)\) between nAbs and efficacy predicts 50% protective neutralization level at 20% average HCS titer.

**Strong correlation between efficacy and neutralization titers calibrated to HCS panels \((\rho = 0.905; p=0.0046)\)**

50% protective titer estimated at 19.9% of mean convalescent level
- Assumes normal distribution of neutralization titers
- Suggests efficacy can be predicted by mean and distribution of nAbs – model correctly estimated efficacy of Covaxin
  - Predicted: 79.4% (76.0%-82.8%)
  - Actual: 80.6%

Adjusting for efficacy against prototype (ancestral) strain (D614G) strengthens relationship

Incorporated post-hoc analyses of Janssen and Novavax Phase IIIs to remove impact of VOCs
- Janssen: 72% efficacy at US site (96.4% D614G)
- Novavax: 95.6% against ancestral strain at UK site

Correlation coefficient = 0.96 with post-hoc analyses; 84.4% variance explained by model

Model may be further strengthened by pending Ox/AZ US Phase III data (76-79% efficacy)
- 4-week interval corresponds better to Phase I schedule
- Potentially less impacted by circulating variants

**Mouse Immunogenicity Study: Preliminary Results**

**S.Africa (B.1.351) Spike-Trimer Protein Expression:**
- Utilizing Clover’s proprietary Trimer-Tag™ technology to achieve stable spike-antigen trimerization and high purity via affinity capture (same platform as Clover’s wildtype SBC-2019 COVID-19 vaccine currently in global Ph 2/3 efficacy clinical study)
- Early-Jan 2021: Completed construct design
- End-Jan 2021: Initial antigen expression achieved
- Early-Feb 2021: Initial Mouse immunogenicity study initiated
- Ongoing: Stable CHO-cell line development & pilot-scale production

**Preliminary Takeaways from Mouse Immunogenicity Study (Day 28 Results):**
- **Monovalent Wildtype Vaccine:** ~9-fold lower neutralization to B.1.351 observed (although titers are ~6x higher than WT human convalescent sera)
- **Monovalent S.Africa (B.1.351) Vaccine:** Fully cross-neutralizes wildtype strain in this study; could be broadly protective against wildtype and all current variants of concern? Advantageous and simpler CMC versus bivalent/multivalent formulation
- **Original Antigenic Sin?** Heterologous prime boost (Wildtype Prime + S.Africa Boost) did not induce additional neutralization to S.Africa (B.1.351) pseudovirus compared to two doses of Wildtype vaccine

**Additional Key Results Expected:**
- Cross-neutralization to UK (B.1.1.7) and Brazil (P.1) variants
- Booster dose (Dose 3) to further evaluate ‘original antigenic sin’
- Cell-mediated immune responses (variant-specific)

---

**Day 28 VNT Results (1 Week Post-Dose 2):**

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Wildtype</th>
<th>Wildtype</th>
<th>Wildtype</th>
<th>Wildtype</th>
<th>Wildtype</th>
<th>Wildtype</th>
<th>Wildtype</th>
<th>Wildtype</th>
<th>Wildtype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td>6,710</td>
<td>8,388</td>
<td>10,276</td>
<td>15,919</td>
<td>1,734</td>
<td>1,398</td>
<td>1,458</td>
<td>7,831</td>
<td>225</td>
</tr>
<tr>
<td>Study 2</td>
<td>1,794</td>
<td>1,458</td>
<td>1,398</td>
<td>1,734</td>
<td>6,710</td>
<td>8,388</td>
<td>10,276</td>
<td>15,919</td>
<td>1,734</td>
</tr>
</tbody>
</table>

Notes: Bars represent geometric mean titer (GMT) values and error bars represent 95% confidence intervals (95% CI) for virus neutralization titers (VNTs) based on pseudovirus assays. Prime (P) + Boost (B) two-dose vaccine regimens. Each dose of monovalent vaccine contains 3 µg of Spike-Trimer antigen for Wildtype (WT) or South African (SA - B.1.351) strains; each dose of bivalent vaccine contains 1 µg of Wildtype Spike-Trimer + 1 µg of SA (B.1.351) Spike-Trimer antigen. Priming dose in all animals utilized CpG 1018 plus alum adjuvants, and half of the animals in each group received boost dose that was adjuvanted (CpG 1018 plus alum) and half received nonadjuvanted boost. VNT results shown represent 4x2 factorial analysis of all animals receiving two doses of vaccine. Human Convalescent Sera (HCS) from symptomatic Chinese COVID-19 patients infected with wildtype SARS-COV-2 (n=7; 1 severe; 4 moderate; 2 unclassified).
Adapted Prototype’ versus ‘Adapted New’
COVID-19 Vaccines – General Overview

Jakob Cramer, MD
Head of Clinical Development
Coalition for Epidemic Preparedness Innovations (CEPI)
‘Adapted Prototype’ versus ‘Adapted New’ COVID-19 Vaccines

General Overview

25th March 2021
New Strains → New Vaccines

- Are approved prototype COVID-19 vaccines **good enough** against currently circulating SARS-CoV-2 variants (of concern) - at least against severe disease?

- We need **more vaccines** but must consider **new circulating virus variants**
  1. Should *new* vaccines be directed against new variants? **Strain change: WHO**
  2. How to approve *prototype vaccines adapted to new variants*? **EMA/FDA/ACCESS guidance**
  3. How to approve *new vaccines targeting new variants*?

Many additional challenges (to be addressed in subsequent workshops):

- Vaccinating seropositive versus seronegative individuals
- Booster vaccination: homologous vaccine or vaccine adapted to new viruses given months after primary immunization with prototype vaccine (against original virus)
- Multivalent vaccines
- Mix and match vaccine regimens...
## Challenging Terminology

<table>
<thead>
<tr>
<th>Term</th>
<th>Explanation</th>
<th>Other terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine</td>
<td><em>‘prototype’</em> Vaccine approved and/or with demonstrated clinical vaccine efficacy against <em>original</em> SARS-CoV-2 virus</td>
<td>‘parent’, ‘original’, ‘current’</td>
</tr>
<tr>
<td></td>
<td><em>‘new’</em> Vaccine without approved <em>prototype</em> based on the identical product/platform</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>‘adapted’</em> Vaccine against <em>variant strain—adapted</em> based on either <em>prototype</em> or <em>new</em> vaccine</td>
<td>‘modified’, ‘variant’, ‘updated’</td>
</tr>
<tr>
<td>Virus</td>
<td><em>‘original strain’</em> Initial SARS-CoV-2 virus (included in <em>prototype</em> vaccines)</td>
<td>‘parent’, ‘initial’, ‘original’</td>
</tr>
<tr>
<td></td>
<td><em>‘variant strain’</em> Mutated SARS-CoV-2 virus with significant modified characteristics that has emerged from the <em>original virus</em></td>
<td>‘new’</td>
</tr>
</tbody>
</table>

Comparing *prototype / adapted* vaccines:
- Same vaccine product (identical platform)
- Same / comparable platform
- Across platforms
## CDP for New Vaccines

<table>
<thead>
<tr>
<th>Option</th>
<th>Vaccine Efficacy demonstrated based on</th>
<th>CDP</th>
<th>Risks / challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) No evidence for correlation between immune response and vaccine efficacy (alternative platform / route of administration)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 1a) Superiority to inactive-comparator (placebo) | Randomized controlled trial  
- Primary objective in seronegatives  
- Target VE: ≥50% (LB 95%CI >30%) | Large sample size  
Placebo-controlled VE trials increasingly challenging |
| 1b) Non-inferiority (NI) to active-comparator | Randomized controlled trial  
- Primary objective in seronegatives  
- Target VE: <10% margin | Access to comparator vaccine  
Time to recruit very large sample size  
Practical challenges |

### B) Evidence for correlation between immune response and vaccine efficacy available and accepted by NRAs / WHO PQ

| 2) Immunobridging (NI) followed by clinical vaccine efficacy | NI to appropriate/approved comparator vaccine based on pre-defined margins for SCRs / GMTs  
- Primary objective in seronegatives  
- Clinical VE based on less stringent requirements (e.g. LB 95% CI = 0%) | Clin. VE based on less stringent criteria probably not acceptable by NRAs / WHO PQ  
Access to comparator, size/time (see 1b)  
May still require post-authorisation vaccine effectiveness |

| 3) Immunobridging (NI) with post-authorisation vaccine effectiveness | NI to appropriate/approved comparator vaccine based on pre-defined margins for SCRs / GMTs  
- (Primary objective in seronegatives)  
- Post-authorisation vaccine effectiveness study | Within identical product/platform versus between products/platforms |

### C) Immune quantitative Correlate of Protection (CoP) available and accepted by NRAs / WHO PQ

| 4) Demonstrate adequate SPR | Establish level of SPR (control group [placebo or active control] only needed for comparing safety / reactogenicity) | NRAs / WHO PQ may still require NI based on SPR |

---

NI = non-inferiority; SCR = seroconversion rate; SPR = seroprotection rate
### Scenarios for Establishing Vaccine Efficacy
directly (via clinical efficacy) / indirectly (via immunobridging)

**Assumption:** Supportive evidence re correlation of immune response with Vaccine Efficacy [no CoP]

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Vaccine type</th>
<th>SARS-CoV-2</th>
<th>Vaccine against original strain authorised?</th>
<th>Pivotal clinical trial?</th>
<th>Comparator vaccine?</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1)</td>
<td>‘prototype’</td>
<td>‘original’ strain</td>
<td>n.a.</td>
<td>Conventional vaccine efficacy trial (data available or expected in near future)</td>
<td>n.a. (placebo) (vaccine already approved or approved in near future) [= default scenario]</td>
</tr>
<tr>
<td>1-2)</td>
<td>‘adapted’</td>
<td>‘variant’ strain</td>
<td>yes</td>
<td>Immune bridging based on NI</td>
<td>‘prototype’ vaccine against original SARS-CoV-2 strain (identical platform)</td>
</tr>
<tr>
<td>1-3)</td>
<td>‘new’</td>
<td>‘variant’ strain</td>
<td>no</td>
<td>1. Immune bridging based on NI [followed by post-authorisation vaccine effectiveness study] 2. Conventional vaccine efficacy trial</td>
<td>1. ‘prototype’ vaccine against original SARS-CoV-2 strain (comparable platform*) 2. placebo</td>
</tr>
<tr>
<td>1-4)</td>
<td>‘new’</td>
<td>‘original’ strain</td>
<td>no</td>
<td>1. Immune bridging based on NI [followed by post-authorisation vaccine effectiveness study] 2. Conventional vaccine efficacy trial</td>
<td>1. ‘prototype’ vaccine against original SARS-CoV-2 strain (comparable platform*) 2. placebo</td>
</tr>
</tbody>
</table>

**IVI:**
- Identical platform = same ‘product’
- Comparable platform = in terms of putative mechanism of protection (i.e. protective immune response primarily based on nAbs / strong T cell response, …)
Planning Pivotal Trials to Establish VE
Adapted versus new COVID-19 vaccines

Global frequencies (coloured by GISAID Clade*)


Wave 1  Wave 1a  Wave 2

Pfizer/BNT  Moderna  Gamaleya
AstraZeneca  J&J  Sinovac  Cansino

Proportion of seropositives, illustrative (original SARS-CoV-2 strain)

Potential recommendation to adapt COVID-19 vaccines to new SARS-CoV-2 strain

*) GISAID clades:
S – original strain
GH – includes B.1.351 lineage
GR – includes B.1.1.7 and P1 lineages

Sensitivity: CEPI Internal

** = Ph3 VE IA data published
--- = Ph3 ‘wave 1’  --- = Ph3 ‘wave 1a’  --- = Ph3 ‘wave 2’
## Sensitivity
CEPI Internal

### Wave 1: ‘Prototype’ approved / with clinical efficacy

**mRNA**
- BNT/Pfizer, Germany/USA
- Moderna, USA

**Viral vector**
- AZ/Uo Oxford, UK
- J&J, USA
- CanSino, China
- Gamaleya (Sputnik V), Russia

**Protein**
- Novavax, USA

**Whole inactivated virion**
- Sinovac, China
- Sinopharm (BIBP), China
- Bharat, India

**Other**
- None

### Wave 1a: Ph3 VE data expected soon

**mRNA**
- CureVac, Germany

**Viral vector**
- Altimmune, USA
- Gritstone, USA

**Protein**
- SK Bio*, SK
- SP/GSK, France/UK
- COVAXXX, USA
- VBI, USA
- SI, India [VLP]*

**Whole inactivated virion**
- IMB, China

**Other**
- Inovio, USA [DNA]
- Zydus, India [DNA]

### Wave 2: VE: Immunobridging?

**mRNA**
- SP/TBio, USA/Canada
- Walvax, China
- Imp. Coll., UK [saRNA]
- Gennova, India [saRNA]

**Viral vector**
- None

**Protein**
- Novavax, USA

**Whole inactivated virion**
- Valneva, Austria

**Other**
- None

---

**Assumptions** made based on publicly available data:

---

For illustration / discussion purposes only

* RBD-based
## Protein-based COVID-19 Vaccines

<table>
<thead>
<tr>
<th>Developer</th>
<th>Construct</th>
<th>Antigen</th>
<th>Adjuvant</th>
<th>No. doses / interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novavax, USA</td>
<td>Nanoparticle</td>
<td>FL spike gp</td>
<td>MatrixM</td>
<td>2 doses, 3 weeks</td>
</tr>
<tr>
<td>Clover, China</td>
<td>S-trimer</td>
<td>FL spike gp</td>
<td>CpG, aluminum phosphate</td>
<td>2 doses, 3 weeks</td>
</tr>
<tr>
<td>BioE, India</td>
<td>RBD N1C1 (Pichia pastoris)</td>
<td>RBD</td>
<td>CpG, aluminium hydroxide</td>
<td>2 doses, 4 weeks</td>
</tr>
<tr>
<td>Medicago, Canada</td>
<td>Plant-based</td>
<td>FL spike gp</td>
<td>ASO3</td>
<td>2 doses, 3 weeks</td>
</tr>
<tr>
<td>SKBio, South Korea</td>
<td>Nanoparticle</td>
<td>RBD</td>
<td>ASO3</td>
<td>2 doses, 4 weeks</td>
</tr>
<tr>
<td>Sanofi Pasteur, France</td>
<td>Recombinant protein</td>
<td>FL spike gp</td>
<td>ASO3</td>
<td>2 doses, 3 weeks</td>
</tr>
<tr>
<td>COVAXX, USA</td>
<td>Multitope peptide based S1-RBD-protein</td>
<td>Parts of several viral Ag</td>
<td>Aluminium phosphate</td>
<td>2 doses, 4 weeks</td>
</tr>
<tr>
<td>VBI, USA</td>
<td>VLP</td>
<td>Modified spike gp</td>
<td>Aluminum phosphate</td>
<td>2 doses, 4 weeks</td>
</tr>
<tr>
<td>Anhui Zhifei, China</td>
<td>Recombinant protein (Chinese Hamster Ovary-CHO Cell)</td>
<td>RBD</td>
<td>Aluminium hydroxide</td>
<td>3 doses, 4 weeks</td>
</tr>
<tr>
<td>Serum Institute of India</td>
<td>VLP (Pichia pastoris)</td>
<td>RBD</td>
<td>Alum vs. CpG</td>
<td></td>
</tr>
</tbody>
</table>
(Placebo-) Controlled Efficacy Trials: Increasingly Difficult

- Vaccination campaigns targeting **high risk groups** for clinical / complicated COVID-19

- Recruiting younger (non-high-risk) population groups: **Significant / increasing practical challenges**
  - Individuals chose not to participate but **wait to be vaccinated with approved vaccine**
  - Even in countries with limited vaccine supply **enrolment of volunteers slows down** → extended recruitment times
  - **Increasing rate of drop-outs** expected over time / as approved vaccines become available
  - **Compromised data quality** (e.g. no local reaction: subjects feel they got placebo and seek vaccination elsewhere)

- Rapidly increasing proportion of trial **population being seropositive**

  ⇒ Increasing unwillingness of developers to consider / conduct conventional vaccine efficacy trials.
  ⇒ Window for pre-licensure vaccine efficacy trial closing?
Variants and Vaccines: Global Public Health Implications

Sylvie Briand, MD
Director, Global Infectious Hazards Preparedness (GIH)
Health Emergencies Programme
World Health Organization (WHO)
Variants and vaccines: global public health implications.

WORKSHOP - 25 March 2021
SARS-CoV2 variants -
Practical considerations for accelerated clinical development in light of current regulatory guidance

Dr Sylvie Briand,
Director Global Infectious Hazards Preparedness (GIH)
Health Emergencies Programme
World Health Organization
Update on key VOCs  
*(as of 23 March)*

Table 2: Overview of emerging information on key variants of concern, as of 23 March 2021*  

<table>
<thead>
<tr>
<th>Nextstrain clade</th>
<th>20H/S01Y.V1</th>
<th>20H/S01Y.V2</th>
<th>20H/S01Y.V3</th>
</tr>
</thead>
<tbody>
<tr>
<td>PANGO lineage</td>
<td>B.1.1.7</td>
<td>B.1.351</td>
<td>B.1.1.28.1, alias P.1*</td>
</tr>
<tr>
<td>Alternate names</td>
<td>VOC 202012/01*</td>
<td>VOC 202012/02</td>
<td></td>
</tr>
<tr>
<td>First detected by</td>
<td>United Kingdom</td>
<td>South Africa</td>
<td>Brazil / Japan</td>
</tr>
<tr>
<td>First appearance</td>
<td>20 September 2020</td>
<td>Early August 2020</td>
<td>December 2020</td>
</tr>
<tr>
<td>Key spike mutations</td>
<td>H69/70 deletion; Y144 deletion; N501Y; A570D; and P681H</td>
<td>L452V/A23K/I224 deletion; E484K, Q498H, N501Y</td>
<td></td>
</tr>
<tr>
<td>Key mutation in common</td>
<td>S236R/G147V/F108 deletion in Non-Structural Protein 6 (NSP6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Countries reporting cases (newly reported in last week)**</td>
<td>125 (7)</td>
<td>75 (11)</td>
<td>41 (3)</td>
</tr>
</tbody>
</table>

*While work is ongoing to establish standardised nomenclature for key variants, these are the names by which WHO will refer to them in this publication.

*Generalized findings as compared to non-VOC strains. Based on emerging evidence from multiple countries, including peer-reviewed research articles and reports from public health authorities and researchers – all subject to ongoing investigation and continuous revision.

**Includes official and unofficial reports of VOC detections in countries among either travelers (imported cases) or community samples (local transmission).

---

https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-23-march-2021
• How long does the natural immunity last?
• How long does the immunity conferred by vaccines last?
• Can people be re-infected, how often?
• What is the impact of each SARS-CoV-2 variant on transmissibility and disease severity? What is the impact on risk groups?
• What is the impact of the variants on public health and social measures, the testing strategy or the tests in use, the management of patients, ...?
• What is the impact of each variant on vaccine efficacy and effectiveness? And does it require to change the vaccine composition?
• What is the impact on research? ...
Timeline
Major infectious threats in the 21st Century & collaboration mechanisms to fight against them
How to build trust during pandemic?
Existing global systems for pandemic vaccine decision: e.g. Seasonal and Non-seasonal (zoonotic) influenza outbreaks

Human infections of non-seasonal influenza reported to WHO, by month of onset

Human infection of zoonotic influenza viruses – **continuous, sporadic**

Emergence and spread of novel H5 (N1, N5 and N8) genetic clade 2.3.4.4 HPAI

Threat of an influenza pandemic – **PERSISTENT – NO Change**

Source: FAO global AIV update, 27 Jan 2021
COVID-19 global monitoring and PH action

Integrated Decision-Making & Public Health Action
Cross-Cutting Coordination Mechanism
Output: Strategic recommendations for COVID-19 prevention & control

Monitoring Groups:
- Surveillance
- EPI/LAB
- Clinical presentation
- Viral Evolution

Variant Forum

Risk assessments

Assessment Forums:
- Vaccines
- PHSM
- Therapeutics
- Impact analyses & Stream-specific recommendations
- Health Systems
- Diagnostics

VOC (Variant of Concern)
Upcoming global consultation: 29 March 2021

• Global Consultation on a Decision Framework for Assessing the Impact of SARS-CoV-2 Variants of Concern on Public Health Interventions
  – 29 March, 13:00-16:30 CET
• Objectives:
  – Review and summarize the existing evidence of the impact of VOCs on public health interventions
  – Engage global stakeholders to outline the information needs and decision-making processes for assessing the impact of VOCIs on public health interventions
  – Using COVID-19 vaccines as an example, review how a decision-making process could look with respect to analyzing the impact of VOCs and issuing policy recommendations
• Outcomes:
  – Established global forum for harmonized coordination and communications regarding VOCs and their impact on public health interventions
  – Decision-making framework that outlines the critical triggers, roles and responsibilities, and information needs and standards to guide policy recommendations regarding the impact of VOCs
  – Common understanding of the current evidence, challenges, and solutions for VOCs and their impact on current and future COVID-19 vaccines
Zooming in: Vaccine & vaccination stream - decision points

What is the impact of each VOC on efficacy and effectiveness?
- By product
  - Existing vaccine
  - Modified vaccine
  - New vaccine
- By risk groups (including age)

What are the implications on products (trigger points)?
Do we need to change the composition?

What are the consequences?
- On vaccination policy?
- On regulatory aspects?
- On COVAX allocation?

How are the various measures used for prevention, mitigation, control of COVID-19?

What is the data/info needed?

What are the methodologies for obtaining data/info?

What groups are involved?

e.g. Vaccination and Public Health measures?
Regulatory Preparedness on Adapting, if Needed, Vaccines for Strain Changes

David Wood, PhD, Independent consultant

Rogerio Gaspar, PhD
Regulation and Prequalification, WHO
Regulatory preparedness on adapting, if needed, vaccines for strain changes

COVAX Workshop
SARS-CoV2 variants - Practical considerations for accelerated clinical development in light of current regulatory guidance
25 March 2021

Rogerio Gaspar / David Wood / Regulation and Prequalification, WHO
What are regulators preparing for?

• A coordinated public-health driven approach on strain composition for modified/new SARS CoV-2 vaccines – **if needed**

• Good linkages with public health authorities

• Three scenarios to consider:
  • Vaccines currently in use – what evidence is needed to decide if modifications are needed – guidance to come from WHO
  • Modifications to vaccines with established vaccine efficacy – guidance already available from regulators and WHO
  • Completely new vaccines – guidance under development
Regulatory guidance to evaluate modifications to vaccines with established efficacy

- Regulators have rapidly developed guidance on evaluation of changes, if needed, to SARS CoV-2 vaccines with established vaccine efficacy

- US FDA, the EMA and the ACCESS consortium (Australia, Canada, Singapore, Switzerland, UK) have published guidance

- WHO has published guidance for PQ/EUL assessments

- Key features of guidance shared during the development process in vaccine cluster (EMA, FDA, HC, WHO), ICMRA and WHO R&D Blueprint meetings

- High level of alignment between regulators on key features

- All guidance’s will be “living guidance” to be modified, if needed, as our knowledge of variants increases
Features of the good alignment between regulators

Assumptions:
✓ Modified vaccine is developed by the same manufacturer and the same manufacturing process;
✓ Neutralizing antibodies are important to protection

• Non-inferiority of the neutralizing antibody response of the modified vaccine compared to the original vaccine
• Primary series to be tested, as well as the effect of a booster dose
• Clinical efficacy will not be required
• Large safety database will not be required
Some manufacturers of vaccines with established efficacy are developing modified vaccines “at risk”

This is useful, since will identify possible manufacturing and evaluation challenges with developing modified vaccines against variants.

Will also help to understand how long the process will take.

Some regions/countries are moving ahead on preparedness for access to modified vaccines e.g. European Commission has launched the “HERA incubator” to develop vaccines against variants, and ramp up industrial production.
Completely new vaccines

• WHO will modify its Target Product Profile based on global public health considerations to guide what is needed

• ACCESS and EMA guidelines already provide some guidance for multivalent COVID vaccines

• Regulators have recognized the need that additional regulatory guidance is required for new vaccines and are actively working on guidance for new vaccines
A globally coordinated response is essential for
- identifying variants of concern,
- their impact on vaccines, and
- any modifications to vaccine composition

Regulatory alignment to assess modifications to SARS CoV-2 vaccines with established efficacy is largely achieved

Further regulatory guidance is needed for vaccine candidates that are in earlier stages of development

Careful messaging is essential on variants so as not to disturb public trust in COVID-19 vaccines
US, EU, ACCESS and WHO Guidance on Strain Change

Adam Hacker, PhD
Head of Global Regulatory Affairs
CEPI
US, EU, ACCESS and WHO Guidance on strain change

Adam Hacker

Head of Global Regulatory Affairs, CEPI
Features of the good alignment between regulators

Assumptions:

- Modified vaccine is developed by the same manufacturer and the same manufacturing process;
- Neutralizing antibodies are important to protection

- non-inferiority of the neutralizing antibody response of the modified vaccine compared to the original vaccine
- primary series to be tested, as well as the effect of a booster dose
- clinical efficacy will not be required
- large safety database will not be required

From David Wood, Regulation and Prequalification, WHO
Scope

- Scope is similar with a requirement for:
  - Parent / prototype vaccine to be approved and
  - The variant / modified vaccine to use the same manufacturing process and sites etc.
  - Assumes that there is no correlate of protection

- US Emergency Use Authorization for Vaccines to Prevent COVID-19 APPENDIX 2: EVALUATION OF VACCINES TO ADDRESS EMERGING SARS-COV-2 VARIANTS  ver 22 February 2021

- EU Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2  ver 25 February 2021

- ACCESS (UK, Australia, Canada, Singapore and Switzerland), Guidance on strain changes in authorised COVID-19 vaccines  ver 4 March 2021

- WHO ADDENDUM to Considerations for Evaluation of COVID-19 Vaccines for Prequalification or Emergency Use Listing, Considerations for evaluation of modified COVID-19 vaccines  ver 12 March 2021
## Terminology

<table>
<thead>
<tr>
<th>Situation</th>
<th>EU</th>
<th>US</th>
<th>ACCESS</th>
<th>WHO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original SARS-CoV-2 strain</td>
<td>Parent strain</td>
<td>Original virus</td>
<td>Initial strain</td>
<td>Original virus</td>
</tr>
<tr>
<td>Original licensed/authorized vaccine (designed against original SARS-CoV-2 strain)</td>
<td>Parent vaccine</td>
<td>Prototype vaccine</td>
<td>Current vaccine</td>
<td>Prototype vaccine</td>
</tr>
<tr>
<td>SARS-CoV-2 variants</td>
<td>Variant strain</td>
<td>Variant of concern</td>
<td>New variant</td>
<td>Variant of concern</td>
</tr>
<tr>
<td>New vaccine designed to protect against one or more SARS-CoV-2 variants</td>
<td>Variant vaccine</td>
<td>Modified vaccine</td>
<td>Updated vaccine</td>
<td>Modified vaccine</td>
</tr>
<tr>
<td>Original vaccine regimen</td>
<td>Primary series</td>
<td>Primary series</td>
<td>Not explicitly referred to</td>
<td>Not explicitly referred to</td>
</tr>
</tbody>
</table>

Original licensed/authorized vaccine (designed against original SARS-CoV-2 strain)
CMC

- Facilities and manufacturing process and control will be identical to that used for the prototype vaccine
- Details of manufacturing development and changes to the manufacturing process necessary due to the novel sequence
- Details of critical aspects of product characterization, sequence identity, potency assay and necessary re-validation of assays and standards required due to the novel sequence
- Shelf life – based on original licensed vaccine, supplement with real time stability

- EU
  - Some guidance on multi-valent considerations
- US
  - Any changes made to the manufacturing process and process control should be discussed with FDA in advance of the EUA amendment submission.

- ACCESS
  - A sufficient number (at least two) commercial scale (pre-) PPQ batches per manufacturing facility (possibly with supporting smaller development batches)
  - If same manufacturing line, adequate data on avoidance of cross-contamination (identity).

- WHO
  - Phylogenetic assessment re “distance” from prototype, for the sequences of the antigenic sites (protein S, protein N) should be provided. Sequence should be comparable to the VoC
Non-Clinical
Non-clinical

• Generally minimal requirements for non-clinical data but should be justified and dependent on platform experience

• EU
  • Bold statement – “No requirement to conduct any further in-vitro or in-vivo nonclinical testing”

• US
  • Immuno data from suitable animal model challenge studies are encouraged and may contribute where clinical immunogenicity studies are ambiguous (can be performed in parallel to clinical studies)

• ACCESS
  • Immunogenicity data, both humoral and cellular, in a relevant animal model will be informative. Comparisons of the prototype and variant vaccines are recommended.
  • Non-clinical protection data from a suitable challenge model may be useful additional data. Where justified, such studies can be performed in parallel to clinical studies. Cross-protection data in animals could test whether the new version of the vaccine is able to provide protection against the existing virus to inform on whether vaccination against both versions of virus should be considered.

• WHO
  • Data on the impact of the antigen change to the immune response may be required. Data should be generated using validated methods
  • Describes immuno data that should be evaluated but also indicates that data on the prototype vaccine may be acceptable
  • Similar statement to FDA re potential to support clinical immunogenicity data
Clinical
Clinical - overview

- Conduct a non-inferiority study comparing the immune response induced by the modified / variant COVID-19 vaccine to that by the prototype / parent COVID-19 vaccine.
  - If unethical to vaccinate with the prototype / parent then the use of historical samples may be possible (link to animal data)
- Primary analysis
  - Neutralizing antibodies elicited by the modified / variant COVID-19 vaccine against the variant strain compared to the neutralizing antibodies elicited by the prototype / parent COVID-19 vaccine against the original virus
  - Non-inferiority margin of -10%
  - Lower bound of the 95% confidence interval around the geometric mean (GMT) ratio should be at least 0.67
- Importantly, where possible should be conducted in unvaccinated subjects with no history of prior Covid-19 infection
- Acceptable to conduct in non-priority groups i.e., in 18- to 55-year-olds
- Booster data required
- Use or calibrate against the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody
SARS-CoV-2-naïve subjects i.e., unvaccinated and with no evidence of prior infection

Inclusion criteria
- Unvaccinated
- No prior Covid-19 infection
- Do not have to include priority groups

Vaccination
- Same dose schedule as approved for parent
- Same blood sampling as parent efficacy data

Neutralizing antibody titres

- **Primary analysis**
  - Difference in seroconversion rates for ① vs. ④ lower bound of 95% CI < -10%.
  - The lower bound of the 95% CI around the GMT ratio ≥ 0.67

**Definitions**
- Seroconversion ≥ 4-fold increase in titre from pre-vaccination to post-vaccination
- Since the primary analysis will be in seronegative subjects, a nominal value should be applied to the pre-vaccination samples to calculate the seroconversion rate.

- **Secondary Analysis**
  - ② vs. ③ <<interesting comparison!>>
  - For vaccines with 2-dose primary schedules, the immune responses after the first dose should be compared along the same lines as for the primary analysis.
  - Present reverse cumulative distribution

- **If administering parent vaccine is unethical: compare ② versus previously obtained data from ①. Ensure same assays, matched population etc.**
- **If ICP specific to vaccine construct**, vaccine as above with just the variant vaccine. The percentage of subjects that achieve titres at or above the ICP (i.e. the seroprotection rate) against the variant strain(s) (i.e. ③) should be determined. Lower bounds of the 95% CI to be agreed with CHMP

---

Sensitivity: CEPI Internal
SARS-CoV-2-naïve subjects i.e., unvaccinated and with no evidence of prior infection

Inclusion criteria
- Unvaccinated
- No prior Covid-19 infection
- Do not have to include priority groups (i.e., in 18-55)

Primary series vaccination
- Same dose schedule as approved for prototype

Neutralizing antibody titres

1. against prototype strain (original virus)
2. against variant of concern (interest)
3. against prototype strain (original virus)
4. against variant of concern (interest)

• Primary analysis
  - nAb seroresponse rate and GMTs for 4 vs. 1
  - non-inferiority margins of -10% for seroresponse rates and 1.5-fold for GMTs

• Additional Analyses (similarly specified for WHO guideline)
  - 3 vs. 1
  - 4 vs. 2

• If high SARS-CoV-2 seroprevalence precludes conducting studies in a SARS-CoV-2 naïve population, then further considerations for characterization of baseline serostatus and vaccine-elicited antibody responses would be needed to ensure that data are interpretable
• Instead of prototype vaccine arm, may use serum samples from a previous study. Ensure same assays, matched population etc.
Subjects previously vaccinated against SARS-CoV-2 i.e., “booster” strategy

Inclusion criteria
Previously vaccinated with parent vaccine primary series
No prior Covid-19 infection
• *Data from previous CT so nAb titres available
• If data not available from previous CT, match population to original CT

Vaccination
Single dose “boost” vaccination
Justify interval between primary series and “boost”

Neutralizing antibody titres

• Primary analysis
  • nAb GMT 4 vs. 5
  • The lower bound of the 95% CI around the GMT ratio ≥0.67

• Secondary Analysis
  • nAb GMT 4 vs. 6
  • Other secondary analysis
    • Comparing seroconversion rates :
      • 5 vs. 6
      • 3 vs. 4

  Or if optional arm included
  • nAb GMT 4 vs. 1
  • The lower bound of the 95% CI around the GMT ratio >1

  • Present reverse cumulative distribution

**CEPI**

- If ICP specific to vaccine construct, vaccine as above with just the variant vaccine. The percentage of subjects that achieve titres at or above the ICP (i.e. the seroprotection rate) against the variant strain (i.e. 6) should be determined. Lower bounds of the 95% CI to be agreed with CHMP

Sensitivity: CEPI Internal
Subjects previously vaccinated against SARS-CoV-2 i.e., “booster” strategy

Inclusion criteria
Previously vaccinated with prototype vaccine primary series

Vaccination
Single dose “boost” vaccination

Neutralizing antibody titres

• Primary analysis
  • nAb seroresponse rate and GMTs for \( 4 \) vs. \( 5 \)
  • non-inferiority margins of -10% for seroresponse rates and 1.5-fold for GMTs

Or if optional arm included
• \( 4 \) vs. \( 2 \)

1. Optional prototype vaccine “boost” arm

2. Prototype vaccine “boost” arm samples against variant strain

3. Previous CT samples against prototype (original) strain

4. Modified vaccine “boost” arm samples against variant strain

5. Previously vaccinated with prototype vaccine primary series
ACCESS Guideline clinical considerations

- Guidance is less specific than the EU or US guidelines re the comparisons to be made – key differences highlighted

- **If in vitro** assays from sera of subjects vaccinated with the current vaccine have shown that cross-reactivity with the new variant is not sufficient, a comparative study of the two vaccines may not be in the best interest of **trial subjects**, a stand-alone immunogenicity and reactogenicity study would be appropriate.

- Include both vaccine-naïve and **subjects already vaccinated** with the current vaccine version; depending on vaccine coverage, the latter may be the focus of the study.

- **Ideally include > 65 years old** <<note “ideally”>>.
**ACCESS Guideline other clinical considerations**

- **Other considerations**
  - For a vaccine using a **viral vector, antibodies against the viral vector should be measured**. Enrolling subjects previously vaccinated within the pivotal trial might provide within-subjects **evaluation of the kinetics of antibodies against the viral vector** and their potential impact on the immune response to repeated vaccinations.
  - Consider additional studies e.g., **homologous vs. heterologous prime-boost regimen**, either of the same vaccine (current and new vaccine versions) or mixing with a vaccine from another platform.
  - **Data on concomitant vaccination e.g., with flu vaccine** (safety including reactogenicity, and immunogenicity) with either the original or the variant vaccine are welcome.
  - Since an updated vaccine variant will build on a previously authorised parent version with established quality, safety and efficacy; from a public health perspective, **it may be justifiable to roll out the new vaccine candidate already in parallel with the previous version in absence of clinical immunogenicity and safety data while these studies are ongoing**. Such approach, only based on non-clinical data, will have to be discussed with Regulatory Authorities.
  - For COVID-19 vaccines which are not yet authorised where an update to the SARS-CoV2 strain is considered, some considerations of this document may apply.
  - **Multivalent**
    - Combination of a new sequence with the current sequence in the new vaccine version (i.e., generation of a bi- or multivalent vaccines) may necessitate additional immunogenicity studies to define the appropriate dose for each sequence and to investigate whether the addition of a second (or subsequent) sequence(s) does not result in an inferior immune response to vaccines with a single sequence. For example, competition at an mRNA level may occur and hamper immunogenicity.
    
    The reactogenicity of the combination should be evaluated, for example in comparison to the single sequence vaccine.
WHO Guideline clinical considerations

• If the prototype vaccine efficacy result was less than 60%, a stricter non-inferiority margin should be used. This is to reduce the risk of listing/approving a modified vaccine with a lower vaccine efficacy than stipulated in the WHO “Consideration for evaluation of COVID19 vaccines,” version November 2020.

• Data from booster studies in which the prototype vaccine and modified vaccine COVID-19 vaccine are administered to people who previously received the prototype COVID-19 vaccine should be provided.

• Provide plan to gather effectiveness data on the variant COVID-19 vaccine.
Safety data requirements

• Data collected during immunogenicity trials (28 days after vaccination?) should be sufficient
• Should include solicited local and systemic adverse events assessed daily for at least 7 days after each study vaccination
• Serious and other unsolicited adverse events (WHO guidance indicates - for the duration of the study)
• Additional safety may be required if safety signal arises from clinical studies

• ACCESS
  • Specific immune power calculation - The number of subjects exposed should inform reactogenicity e.g., around 300 per cohort (e.g., 300 vaccine-naïve subjects or 300 subjects already vaccinated with the current vaccine version) would achieve a precision of about ±5% in the estimate of reactogenicity based on the 95% confidence interval (CI).
  • It may be justifiable to roll out the new vaccine candidate already in parallel with the previous version in absence of clinical immunogenicity and safety data while these studies are ongoing.
  • Updated Risk Management Plan (including country-specific Annex/Addendum) would be required to ensure that adverse events can be appropriately captured for both the variant and prototype vaccine versions.
  • Traceability of the brand and batch, distinguishing suspected ADRs with new and old formulations and collecting quality information on immunisation and medical history need to be a key focus of the updated RMP
Break
Part 2:

Use Cases & Panel Discussions
Vaccine Clinical Development Plan-Approaches in the context of products with EUA

Anh Wartel, MD
Deputy Director General, CARE Unit, International Vaccine Institute (IVI)
COVAX Workshop
SARS-CoV-2 Variants

Vaccine Clinical Development Plan
Approaches in the context of products with EUA

Anh Wartel, MD
Deputy Director General, CARE Unit, IVI
25th March, 2021
Background

- 310 vaccine candidates are being tested, as of mid-March 2021¹
  • 81 in clinical testing (i.e., 27 in phase I; 25 in phase I/II; 6 in phase II; **18 in phase III**; and 5 in phase IV)
  • At least **13 in use**

- More than 447 million doses have been administered – Enough to vaccinate **2.9%** of the Global Population²

- SARS-CoV-2 variants have emerged since Q3, 2020: UK (B.1.1.7), South Africa (B.1.351), and Brazil (P1)³

- Concerns of variants: increased transmission; increased morbidity and mortality; **immune escape with reinfection risk and loss of efficacy**

- 15 vaccines are approved for emergency use by regulatory agencies and vaccines rollout programs on ongoing.

- Vaccine efficacy has been documented with various vaccine platforms in several countries, including those with the circulating variants.

- In vitro immunogenicity data are available against several variants of concern.

- There is a need to generate additional clinical data for EUA vaccines, in the context of variants.
Setting the scene - scenario we are focusing on...

- In terms of vaccine development stage and scientific knowledge, we have made great progress.

- Several EUA vaccines based on vaccine efficacy endpoints, with a satisfactory safety profile after regulatory review are approved.

- Data suggest a strong correlation between humoral immune response and vaccine efficacy with growing acceptance by regulators.

- Then emergence of variants is worrisome as well as its implications on clinical development plans for the EUA vaccines.

- Available guidelines from EMA/US FDA/ACCESSS/WHO helps in the design of additional studies in the post-authorization stage for vaccine developers – Immune bridging based on non-inferiority studies is encouraged.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Vaccine type</th>
<th>SARS-CoV-2</th>
<th>Vaccine against original strain authorized?</th>
<th>Pivotal clinical trial?</th>
<th>Comparator vaccine?</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-2)</td>
<td>‘adapted’</td>
<td>‘variant’ strain</td>
<td>yes</td>
<td>Immune bridging based on NI</td>
<td>‘prototype’ vaccine against original strain (within platform)</td>
</tr>
</tbody>
</table>
In light of EMA and US FDA regulatory guidance, additional considerations for discussion – Baseline and Immune Response Assessment

- Countries of choice for clinical trials and study population for immunogenicity data comparisons are important.

- Baseline and Immune Response Assessment
  - EUA vaccine (prototype vaccine) used as a comparator should be provided by the manufacturer.
  - Given the deployment of National Immunization program and variants circulation, baseline profile of the subjects enrolled may differ compared to the previous studies with the prototype vaccine. (i.e., harder to find seronegative subjects and meet the primary analysis with the four-fold rise definition).

⇒ Immunogenicity data comparison may be difficult since the prototype and adapted vaccines populations don’t match.

- In case it is unethical to use prototype vaccine in clinical trial due to poor protection from variants and, therefore, a historical control is needed.
In light of EMA and US FDA regulatory guidance, additional considerations for discussion – Immunobridging assays

- **Characterization**: regulatory accepted, qualified immunological assays conducted under GCLP, and for clinical samples collected from EUA prototype vaccine comparator, and new variant vaccine-vaccinated participants
- **Readout**: relative immunogenicity to an appropriate control standard (e.g., NIBSC International Standard)
- **Clinical relevance**: demonstrated clinical association of prototype vaccine immune bridging readout to vaccine efficacy with one or more EUA prototype vaccine preferably including the same precedent prototype vaccine class; if feasible/available, clinical association of variant vaccine Immunobridging readout to variant strain.

For example, robust evidence that neutralizing antibody (NAb) response to the variant strain:
- parallels the neutralization levels induced by the “prototype” vaccine to the prototype strain,
- matches or surpasses the neutralization levels observed among individuals infected with the variant strain

=> **Suggestive evidence** from four different COVID-19 platforms (mRNA, adenovirus, subunit adjuvanted and inactivated virus) supports a relative NAb response as a candidate immunobridging assay.
In light of EMA and US FDA regulatory guidance, additional considerations for discussion – Lab assays and variants availability

- According to US FDA, for variant vaccines using the same platform as used for EU approval, that **immunobridging should be acceptable** to approve variant/adapted vaccines comparing prototype neut Abs in a prototype neut assay to variant neut Abs in a variant neut assay.

- On one hand, it is encouraged to include the **International standard (IS)** as a benchmark.

- However,
  - The CoV-2 prototype and variant NAb assays are not the same - will be challenging to show NI for the variant.
  - South Africa is reporting data and mentioning **differences** between viruses in cell culture.
  - An IS for each variant should solve this issue, but it will take some time.

- **Assay’s characteristics** may have an impact on the readout of clinical sample testing (e.g., low or high titers with the adapted vaccine compared to the titers elicited with the prototype vaccine).

- For now, it would be good to get a **landscape of circulating variants of concern**, particularly sequence-confirmation of which variant did **infected** for the IS effort.

---

**SARS-CoV-2-naive subjects**

i.e., unvaccinated and with no evidence of prior infection

**Inclusion criteria**

- Unvaccinated
- No prior COVID-19 infection
- Clinical Trial
- Do not have COVID-19

**Primary analysis**

- Difference in seroconversion rates for prototype and variant
- Use of IS for prototype and variant
- Use of IS for prototype and variant
- Use of IS for prototype and variant
- Use of IS for prototype and variant
- Use of IS for prototype and variant
- Use of IS for prototype and variant
- Use of IS for prototype and variant
- Use of IS for prototype and variant

**Secondary Analysis**

- Protocol to include an additional group of volunteers for the variant
- Protocol to include an additional group of volunteers for the variant
- Protocol to include an additional group of volunteers for the variant
- Protocol to include an additional group of volunteers for the variant
- Protocol to include an additional group of volunteers for the variant
- Protocol to include an additional group of volunteers for the variant
- Protocol to include an additional group of volunteers for the variant
- Protocol to include an additional group of volunteers for the variant
In light of EMA and US FDA regulatory guidance, considerations to be taken – Immune correlate of protection is known

- In both scenarios (i.e., SARS-CoV-2 naïve subjects and previously SARS-CoV-2 vaccinated subjects),
- if ICP is specific to a vaccine construct, vaccine should be as above with just the variant vaccine. The percentage of subjects that achieve titers at or above the ICP (i.e., seroprotection rate) against the variant strain should be determined.

Furthermore, the LB of 95% CI should be agreed with CHMP in EU.
- US FDA guidance, GMTs NI margin require is 1.5 -fold increase.
In light of ACCESS Guideline Clinical Considerations

- All guidelines (EMA/US FDA/ACCESS) recommend the collection of the same safety data (i.e., solicited local and systemic adverse events for at least 7 days post injection as well as serious and other unsolicited adverse events) during the immunogenicity trials with short-term data up to 2 months depending on the vaccine regimen.

- Although the ACCESS guideline is less specific compared to EMA and US FDA guidance, there is recommendation on the clinical data sample size for adapted vaccine:
  
  o Immunogenicity bridging data: 300 subjects per arm
  
  o Safety bridging data while accumulating the safety data from the prototype vaccine: 300 exposed subjects (i.e., 300 vaccine-naïve subjects or 300 already vaccinated with the prototype vaccine) would achieve a precision of about 5% in the estimate of reactogenicity based on the 95% CI.

⇒ The clinical database may be sufficient if prototype data is considered.
Interestingly, from a public health perspective it may be justifiable to roll out the adapted vaccine candidate in parallel with the previous prototype vaccine:

- in the absence of clinical safety and immunogenicity data,
- as an adapted vaccine candidate will build on previously authorized prototype vaccine with established quality, safety, immunogenicity, and efficacy,
- but such approach will have to be discussed with Regulatory Authorities.

⇒ Engagement of developers with regulators is critical and urgent.
Guidelines from EMA/US FDA/ACCESS/WHO have been issued early in the process and are helpful for vaccines developers.

For vaccine developers that have prototype vaccine and have demonstrated efficacy, immune bridging based on NI is recommended by regulators – immunogenicity assumptions will drive the size of the trial.

Generation of additional safety data should be discussed with regulators.

Further clarity is needed – what assays are needed?; How to interpret the NI of immune response using different assays and potentially testing prototype and adapted vaccines in different populations?
More Considerations

- Wherever these new variant vaccines are tested and deployed, one must consider the following:
  
  o **pharmacovigilance** must be **strengthened** to assess the safety of these adapted vaccines;
  
  o **surveillance of emerging variants** under immune pressure is **crucial**; and
  
  o **virus sieve analysis** of breakthrough infections should be put in place.

- With sequences and characteristics of the vaccines, can we reeducate the immune response system? Are there any **lessons learnt** from **flu vaccine**...
Thank You!
Panel Discussion: Products with or without EUA, Full Registration

Moderated By:
Jakob Cramer, MD
Head of Clinical Development
Coalition for Epidemic Preparedness Innovations (CEPI)
Discussion Panel Members – Variant vaccines adapted from prototype vaccine which already achieved authorization

**Panel Members**

- **Gustavo Mendes Lima Santos**, ANVISA (Brazil)
- **Phil Krause**, US FDA
- **Marco Cavaleri**, EMA

Speakers joining the panel:

- **Anh Wartel**, IVI
- **Sylvie Briand**, WHO
- **David Wood**, Independent Consultant
- **Adam Hacker**, CEPI

**Potential Discussion Questions**

1. **Reacting quickly to new variant strains**: Can you please share a few thoughts on (absence of) validated assays and (lack of) international standards for new variant strains regarding immunobridging trials?

2. **Without a quantitative CoP but with international standards in place** – could there be a pathway forward to authorize future COVID-19 vaccines adapted to new variant strains based on immunogenicity only (without immunobridging, e.g. influenza)?

3. **NI in seronegatives**: It will be increasingly difficult to recruit populations seronegative to both the original and the variant strain. Could this be reflected by using appropriately defined seroconversion rates (SCR) rather than seroresponse rates (SRR)?

4. **For 2-dose vaccines**, immunobridging will be assessed post 2nd dose. What are your thoughts regarding immunobridging post 1st dose in seropositives (to possibly establish single dose regimen in previously vaccinated / infected persons)?
Pathways for Approval of COVID-19 Vaccines Based on SARS-CoV-2 Variant Strains

Jorge Flores, MD
Margaret Toher, PhD
David Kaslow, MD
Center for Vaccine Innovation and Access (CVIA)
Pathways for Approval of COVID-19 Vaccines Based on SARS-CoV-2 Variant Strains

Jorge Flores, Margaret Toher and David Kaslow

Center for Vaccine Innovation and Access (CVIA)
Pathways for approval of COVID-19 vaccines based on variant SARS-CoV-2 strains

Alignment on nomenclature used in this presentation

- **Prototype vaccine:** vaccine based in the original SARS-CoV-2 virus
- **Adapted vaccine:** vaccine against variant strain (based on the prototype vaccine)
- **Approval:** Emergency Use approval (EUA), Emergency Use Listing (EUL), Conditional Marketing Authorization (CMA)
Approval of adapted COVID-19 vaccines based on prototype vaccines not already approved

Framing the Problem

• Current regulatory guidance for adapted vaccines do not explicitly address manufacturers without an existing approved prototype vaccine
• Such manufacturers are considering parallel development of prototype and adapted vaccines; their prototype vaccine candidates fall into one of two classes:
  • Those with an approved *precedented* vaccine (e.g., mRNA, adenovirus, inactivated virus)
  • Novel vaccines, without existing approved prototype made by other manufacturer (e.g., recombinant subunit, DNA)
• Large placebo-controlled clinical efficacy trials have rapidly become infeasible to conduct

Framing the Solution(s)

• Given that current regulatory guidance provides an immunobridging pathway to approval for adapted vaccines for manufacturers with approved prototype vaccines, under what conditions and by what clinical design might immunobridging studies be an acceptable pathway for approval of adapted vaccines from manufacturers without an approved prototype vaccine
  • if adapted vaccine is based on a *precedented* class?
  • if adapted vaccine is based on a *novel* class?
• When immunobridging is not an acceptable pathway for approval, then what alternative clinical efficacy trials might feasibly be conducted?
Three simplifying assumptions for a new adapted vaccine based on preceded type prototype vaccine class

- **Efficacy:**
  Approval of adapted vaccines based on immunogenicity bridge to an existing approved prototype vaccine by another manufacturer
  - *Immunobridging has been used to bridge immunogenicity to efficacy through use of another manufacturer’s approved vaccine (e.g., meningococcal and pneumococcal vaccines)*
  - *Data from testing COVID-19 vaccines from diverse platforms indicates a strong correlation between the vaccine induction of neutralizing antibodies and clinical efficacy*

- **Safety:**
  Robust combined prototype and adapted vaccines safety databases submitted for approval review
  - *Safety can also be bridged between an adapted vaccine and its prototype vaccine manufactured in the same platform*

- **Post-approval commitments:**
  Conduct and report during initial post-approval introduction
  - clinical endpoint data (effectiveness)
  - additional safety data through active and passive surveillance (pharmacovigilance)
Expedited approval of adapted vaccines for vaccines already approved for emergency use (as discussed in the previous presentation)
Approval of adapted vaccines when a prototype vaccine has not yet been approved
Early clinical development of adapted vaccines

Objectives:
- Prove safety
- Bridge immunogenicity to prototype vaccine (if available)
- Bridge immunogenicity to approved adapted vaccine from different developer*

Endpoints:
- Safety (reactogenicity, AEs, SAEs)
- Neutralization of parental and variant strains

Study arms:
- Adapted vaccine
- Prototype vaccine from same developer and/or
- Approved prototype vaccine from different developer*
  ~ 300 subjects per arm

Analysis:
- Non-inferiority of seroresponse rates and GMT

* Possible for vaccines using similar platforms
Advanced development of adapted vaccines

Try to exploit the potential for immunobridging as much as possible

• to a previously approved adapted vaccine manufactured with the same / similar / equivalent platform
• to a previously approved adapted vaccine manufactured with different platform

When no immunobridging is possible (different antigens, different platforms, different mechanisms of action) clinical efficacy will have to be proven
Advanced development of an adapted vaccine when a prototype vaccine is in development

When adapted vaccine in the same class is approved

<table>
<thead>
<tr>
<th>Phase 3</th>
<th>Bridge to approved adapted vaccine from a different manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose</td>
<td>IMMUNOBRIDGING</td>
</tr>
<tr>
<td>Objectives</td>
<td>SAFETY</td>
</tr>
<tr>
<td>Arms</td>
<td>2 arms: adapted vaccine, approved adapted vaccine</td>
</tr>
<tr>
<td>Key Comparisons</td>
<td>NAb non-approved vs approved adapted vaccine</td>
</tr>
<tr>
<td>Approximate size/arm</td>
<td>2-3K</td>
</tr>
</tbody>
</table>

When no approved adapted vaccine is available to bridge or the vaccines belong to different classes

<table>
<thead>
<tr>
<th>Phase 3</th>
<th>Direct Demonstration of Vaccine Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose</td>
<td>CLINICAL EFFICACY</td>
</tr>
<tr>
<td>Objectives</td>
<td>SAFETY</td>
</tr>
<tr>
<td>Arms</td>
<td>2 arms: adapted vaccine, prototype vaccine</td>
</tr>
<tr>
<td>Key Comparisons</td>
<td>Covid-19 Attack rates adapted vaccine vs comparator</td>
</tr>
<tr>
<td>Approximate size/arm</td>
<td>20-30K</td>
</tr>
</tbody>
</table>
**Sequential immunobridging**

Adapted vaccine to approved prototype vaccine of a different class

Platform A = Prototype and adapted subunit vaccines

Platform B = Approved prototype recombinant Adeno vaccine

<table>
<thead>
<tr>
<th>Step 1</th>
<th>Vaccine</th>
<th>Safety population</th>
<th>Immunogenicity subcohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>arm 1</td>
<td>Platform A prototype vaccine</td>
<td>3000</td>
<td>300</td>
</tr>
<tr>
<td>arm 2</td>
<td>Platform B approved prototype vaccine</td>
<td>3000</td>
<td>300</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Step 2</th>
<th>Vaccine</th>
<th>Safety population</th>
<th>Immunogenicity subcohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>arm 3</td>
<td>Platform A adapted vaccine</td>
<td>3000</td>
<td>300</td>
</tr>
</tbody>
</table>

**Analytical approach**

<table>
<thead>
<tr>
<th>comparison</th>
<th>endpoint</th>
<th>design</th>
<th>Criterion 1</th>
<th>Criterion 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>arm 1 vs arm 2</td>
<td>NAb to original strain</td>
<td>Non-Inferiority</td>
<td>GMT 0.67-1.5X*</td>
<td>S-response rate (-10%)*</td>
</tr>
</tbody>
</table>

If criteria met go to step 2

STEP 2

| arm 2 vs arm 3 | NAb to variant | Non-Inferiority | GMT 0.67-1.5X* | S-response rate (-10%)* |

If criteria met, submit for approval

**Immunogenicity endpoints: Neutralizing antibody to Prototype and variant viruses**
The More Challenging Path to approved for Variant Vaccines Whose Prototypes are not yet Approved

More straightforward pathway (EU approved for prototype)

- EU approved prototype
- same manufacturer
- monovalent
- same platform
- same formulation
- no new adjuvant
- similar construct
- same route
- same schedule
- different sequence

- prototype not approved
- different manufacturer
- bivalent - polyvalent
- different platform
- different formulation
- different adjuvant
- different construct
- different route
- different schedule
- different sequence

Examples:

- Biosimilars ("identical" but manufactured by a different developer)
- “Similar” platforms (e.g., new Ad vector)
- New inactivation method
- New adjuvant
- Additional doses
- Intranasal administration
- Mixed with initial vaccine (bivalent)

If two or more variables are introduced at the same time – can immunogenicity bridging be applied?
If two or more differences are introduced concurrently – will immunobridging still be acceptable?

1. prototype not approved
2. bivalent - polyvalent
3. different platform
4. different formulation
5. different adjuvant
6. different construct/core sequence
7. different route
8. different schedule
9. different strain sequence
10. different manufacturer
If Immunobridging is not allowable, what clinical studies need to be conducted for new adapted vaccines

• Comparator clinical efficacy trial with a variant-matched approved adapted vaccine (non-inferiority / superiority)
  
  *it will be challenging to identify an approved adapted vaccine comparator*

• Comparator efficacy trial with an approved prototype vaccine
  
  *This will be required if there is evidence that the epidemics is mixed, included continuing circulation of the prototype strains*

  *A placebo-controlled study could potentially be justified if the variant has “taken over” the epidemics.*

• Effectiveness study
  
  *Would the regulators / country authorities allow the conduct of a circumscribed effectiveness study (e.g., a stepped-wedge designed trial)? before and towards approved

Notes:

1) The studies above would have to be properly powered to meet the original efficacy expectations from WHO, FDA, EMA, etc.

2) For efficacy evaluations the adapted vaccine under test does not necessarily have to share features with the comparator vaccine (i.e., different platform, adjuvant, are OK)
Summary: key takeaways

- **Immunobridging (IB):** a potential expedited pathway for new adapted vaccines from manufacturers without existing approved prototype vaccines, particularly when adapted vaccine based on precedent class of approved prototype vaccine is available.

- Likelihood of acceptance depends on difference between new adapted vaccine candidate to approved prototype vaccine providing immunobridging (platform, adjuvant, etc.).

- Sufficiently large safety database will be needed.

- Post-approval pharmacovigilance and effectiveness studies shall be initiated at introduction.

- If immunobridging is not acceptable and:
  - An approved adapted vaccine is available as a comparator, then non-inferiority efficacy studies may be the next best alternative; however, the study size may be infeasible.
  - No approved vaccine is available with demonstrated efficacy against the variant(s) of concern, then clinical efficacy trial design will depend on the circulating strains and efficacy of the available approved prototype comparator; in rare instances, a placebo-controlled trial might be feasible to conduct.
Additional research needed to inform decisions re. immunobridging vs clinical efficacy trial

• Further characterize the Immune response to variant strains.
• Develop standard reagents (antibodies and virus panels) and validate assays
• Continue work on Correlates of Protection
• Refine preclinical challenge models
  • Passive transmission of human antibodies
  • Cross-protection studies
• Develop CHIM
• Strengthen natural history studies:
  • Breadth and evolution of the immune response
  • Emergence of sequence variants at the individual level
• Response to vaccination among previously infected subjects
  • With the original virus
  • With variant vaccines
Thanks!

Jorge Flores, Margaret Toher and David Kaslow
Panel Discussion: Products in Development Without Path to Efficacy / EUA

Moderated By:
Peter Dull, MD
Deputy Director,
Integrated Clinical Vaccine Development,
Bill & Melinda Gates Foundation (BMGF)
Discussion Panel Members: Pathway for variant vaccines for which no prototype vaccine has been authorized

Panel Members

- **Gustavo Mendes Lima Santos**, ANVISA (Brazil)
- **Phil Krause**, US FDA
- **Marco Cavaleri**, EMA

Speakers joining the panel:

- **Jorge Flores**, CVIA
- **David Kaslow**, CVIA
- **Sylvie Briand**, WHO
- **David Wood**, Independent Consultant
- **Adam Hacker**, CEPI

Potential Discussion Questions

1. **Platform pairings?:** An immuno-bridge "across vaccine platforms" is a challenging request. Are there certain platforms more amenable to such comparisons (e.g., sub-unit to inactivated? vector to RNA?)

2. **Safety database?:** Studies have been very large for initial efficacy studies driven by the need to accumulate sufficient cases rapidly. Presuming a licensure pathway is found acceptable based on immunogenicity, is 3000 vaccine-exposed subjects a reasonable target for an adult indication with a known vaccine platform?

3. **Comparator vaccine?:** There are real and practical challenges to acquiring sufficient quantity of comparator vaccine for head-to-head studies. If the 'appropriate' comparator is not accessible, are there design consideration a sponsor can propose to mitigate concerns (e.g., superiority success criteria)

4. **Beyond antibodies?:** What additional immunologic characterization is minimally expected in phase 3 if the phase 1 and 2 studies have extensively characterized the product if cross-platform comparisons are entertained?

5. **Back neutralization?:** What are implications of lower neutralizing antibodies from the variant vaccine against the prototype virus in comparison with prototype vaccine against prototype virus, presume response are well above HCS panel titers?
Wrap Up & Next Steps

Jakob Cramer, MD
Head of Clinical Development
Coalition for Epidemic Preparedness Innovations (CEPI)
Closing remarks

• Thank you all for your participation and engagement today

• Workshop report distributed shortly to summarize today’s conversation

• We will continue to share resources at the website here: https://epi.tghn.org/covax-overview/clinical-science/

• Please consider sharing your thoughts and suggestions on this and/or future workshop in our Discussion Forum https://epi.tghn.org/community/groups/group/cwsg/

• Next workshops:
  ➢ COVAX Maternal Immunisations WG: 13th April 2021
  ➢ COVAX CMC/Clin Dev SWAT teams: 14th April 2021 (multivalent COVID-19 vaccines)

• The COVAX Clinical SWAT Team plans to continue sharing learnings across developers as we pursue our common goal – a global supply of safe and effective vaccines
Clinical Development & Operations SWAT Team